John C. Lechleiter, Ph.D.

Daniel Tassé

Research in Your Backyard: Elevating the Science of Clinical Trials

In the video featured, learn what thought leaders and experts talked about when they came together to discuss the economic benefits of research and other innovation concepts.

The joint event, hosted by PhRMA and We Work for Health brought together governors, pharma executives, and industry experts to discuss the future of the biotechnology industry in the United States, as well as new innovations that are transforming the way medicine is practiced in the country and around the world.

Robin Elliott - PARKINSONS

How can we find better treatments for Parkinson's disease (PD) at a faster pace? At the Parkinson’s Disease Foundation (PDF), we argue that one solution is ensuring that people with Parkinson’s are primary partners in research alongside scientists, industry and government.  The innovation of patient engagement is something that the medical community is starting to recognize as a necessary component to patient-centered research and care delivery.

Robin Elliott


Lisa Treviño

Peter Schmidt - PARKINSONS

The greatest issue facing Parkinson’s patients today is the lack of any therapy that could slow the disease progression.  In its early and mid stages, Parkinson’s primarily affects the dopamine system and, as we have seen in studies of placebo response, the dopamine system responds to hope.  The impact of a therapy that can slow the disease would go beyond just the benefit of neuroprotection, it would help people with Parkinson’s to see a brighter future.  Research has shown that the placebo response in randomized trials is affected by the probability of the s

Peter Schmidt

Todd Sherer - PARKINSONS

Parkinson’s patients need a cure. The millions living with the disease today, the many more who will age into Parkinson’s risk and their loved ones need a therapy that could prevent, stop or halt progression of the disease. No current treatments impact the disease process itself; they only treat the symptoms. In addition, the symptomatic treatments at our disposable leave much to be desired. Some symptoms — such as cognitive decline — have no therapeutic option.


Subscribe to PhRMA RSS